Immunovative develops products which integrate with novel protocols to stimulate a cascade of immune events in a patient to elicit the Mirror EffectTM mechanism. By developing products as immune tools and then integrating the products into steps of a protocol, we can accomplish unprecedented control of the immune system. This control can be realized even in heavily pre-treated, high tumor burdened, metastatic cancer patients or patients suffering from incurable infectious diseases (such as HIV, hepatitis, herpes, ebola, malaria, etc). Patients at this late stage of disease were previously thought to have been poor candidates for immunotherapy. With a single product delivered by different routes at different times, strategically planned into a protocol, we can train the immune system to identify cancer or viral infected cells, create and effective immune response and imprint this response over the resident failed response and disable the ability of the cancer or virus to evade immune attack.